HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT
HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT
HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT, published by HL7 International Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/standardhealth/fsh-ae/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicationAdministration
Resource MedicationAdministration "medadmin-doxorubicin-persona-2"
status: completed
category: Outpatient (MedicationRequest Category Codes#outpatient)
medication: doxorubicin hydrochloride 20 MG per 10 ML Injection (RxNorm#1790099)
subject: Patient/PatientPersona2 " C."
effective: 2020-12-01
reasonReference: Condition/primary-cancer-condition-persona-2
request: MedicationRequest/medrequest-doxorubicin-persona-2
note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2020-12-01)
| Route | Dose |
| Intravenous route (qualifier value) (SNOMED CT#47625008) | 105.96 mg (Details: UCUM code mg = 'mg') |